In addition, FAK inhibitor PF562271 was also included in PROTAC study, leading to the establishment of PROTAC FC-11 that exhibited rapid FAK degradation with picomolar DC50 in several cancer cells [247]. This evidence concerns the gene PTK2 and cancer.